Israel’s KAHR Medical has received US FDA approval to begin Phase 1 & 2 clinical (human) trials of its DSP107 treatment of advanced solid tumors (reported here previously). The trials will assess DSP107 both by itself and in combination with Roche’s atezolizumab.

https://www.jpost.com/health-science/fda-gives-jerusalem-based-company-go-ahead-to-start-cancer-drug-trials-638355

https://www.youtube.com/watch?v=D2NLNV3CB2U

https://kahr-medical.com/technology/pipeline/